[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"delirium-of-mixed-origin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:delirium-of-mixed-origin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100425758","phase-1-effects-of-dexmedetomidine-in-patients-with-agitated-delirium-in-palliative-care-100425758",false,"NCT04824144","Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care","Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care: an Open-label Phase 1\u002F2 Proof-of-concept, Feasibility, and Dose-finding Clinical Trial","Inclusion Criteria:\n\n1. Adult patients (≥18 years)\n2. Admitted to a participating inpatient palliative care unit\n3. Meeting one of the following criteria:\n\n   1. Agitated delirium: (i) Richmond Agitation-Sedation Scale for palliative care patients (RASS-PAL) score of +2 or greater and (ii) Confusion Assessment Method (CAM) positive status and (iii) Without a known potentially reversible cause (e.g. hypercalcemia, specific medication infection, etc.), or in whom the patient\u002FSubstitute Decision Maker (SDM) has requested not to treat the cause.\n   2. Previous history of delirium (in the last 6 months)\n   3. Patient is within the last two weeks of life and is expected to die during this admission (MRP judgement)\n\nExclusion Criteria:\n\n1. Hemodynamic instability (systolic blood pressure \\\u003C80mmHg)\n2. Bradyarrhythmia (heart rate \\\u003C 60) at baseline\n3. Patients on verapamil, diltiazem, or beta-blocker (patients are eligible if these medications are stopped prior to receiving dexmedetomidine)","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this multi-centre phase I\u002FII open-label, single-arm study is to determine the feasibility, optimal dose, and preliminary efficacy of dexmedetomidine to manage agitated delirium among patients near the end of life followed by a palliative care provider in a non-monitored setting. Fifty patients will receive dexmedetomidine (0.4 mcg\u002Fkg\u002Fhour, titrated up to 1.0 mcg\u002Fkg\u002Fhour) subcutaneously. Feasibility (recruitment rate, cost), safety (rate of adverse events), dosing, and preliminary efficacy (agitation, delirium severity) will be measured.",[27,28],"Hyperactive Delirium","Delirium of Mixed Origin",[30,31,32,33,34],"Dexmedetomidine","Agitation","Delirium","Palliative","End of life","RECRUITING","2025-04-11",{"date":38,"type":39},"2025-04-15","ACTUAL",{"date":41,"type":39},"2024-01-30",{"date":43,"type":20},"2026-03-31",{"name":45,"class":46},"Bruyère Health Research Institute.","OTHER",3]